當前位置：首頁 SCI期刊 SCIE期刊醫學中科院4區 JCRQ3 期刊介紹(非官網)

Biomarkers In MedicineSCIE

國際簡稱：BIOMARK MED 參考譯名：醫學生物標志物

中科院分區
4區
CiteScore分區
Q2
JCR分區
Q3

基本信息：: ISSN：1752-0363; E-ISSN：1752-0371; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區：ENGLAND; 出版商：Future Medicine Ltd.; 出版語言：English; 出版周期：Bimonthly; 出版年份：2007; 研究方向：醫學-醫學：研究與實驗

評價信息：: 影響因子：1.9; H-index：37; CiteScore指數：3.8; SJR指數：0.481; SNIP指數：0.491

發文數據：: Gold OA文章占比：10.80%; 研究類文章占比：89.16%; 年發文量：83; 自引率：0.0454...; 開源占比：0.0984; 出版撤稿占比：0; 出版國人文章占比：0.32; OA被引用占比：0.1210...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Biomarkers In Medicine期刊介紹

Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.

Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.

As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.

Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.

Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.

期刊簡介Biomarkers In Medicine期刊介紹

《Biomarkers In Medicine》自2007出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：較慢,6-12周
醫學
MEDICINE, RESEARCH & EXPERIMENTAL
SCIE
中科院4區
非預警

Cite Score數據（2024年最新版）Biomarkers In Medicine Cite Score數據

CiteScore：3.8
SJR：0.481
SNIP：0.491

學科類別	分區	排名	百分位
大類：Medicine 小類：Biochemistry (medical)	Q2	34 / 72	53%
大類：Medicine 小類：Drug Discovery	Q3	95 / 157	39%
大類：Medicine 小類：Clinical Biochemistry	Q3	75 / 117	36%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Biomarkers In Medicine 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	4區	MEDICINE, RESEARCH & EXPERIMENTAL 醫學：研究與實驗	4區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Biomarkers In Medicine JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q3	127 / 189	33.1%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q3	131 / 189	30.95%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
CHINA MAINLAND169
USA63
Italy38
Turkey36
GERMANY (FED REP GER)19
Brazil18
England18
Iran17
Greece13
Spain11

本刊中國學者近年發表論文

1、Association of TLR4 and TLR9 gene polymorphisms with the risk and progression of cervical lesions in HPV-infected women
Author: Zhang, Chunlin; Yang, Zhiping; Luo, Ping; Ye, Mengxia; Gong, Ping; Gong, Quan; Mei, Bing

Journal: BIOMARKERS IN MEDICINE. 2022; Vol. 17, Issue 3, pp. 133-142. DOI: 10.2217/bmm-2022-0702
2、Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma
Author: Sun, Xiaoqing; Cao, Jianghua; Sun, Peng; Yang, Hang; Li, Huan; Ma, Wenjuan; Wu, Xianqiu; He, Xiaohua; Li, Jing; Li, Zhiming; Huang, Jiajia

Journal: BIOMARKERS IN MEDICINE. 2022; Vol. 17, Issue 3, pp. 143-158. DOI: 10.2217/bmm-2022-0764
3、Low expression of MEOX2 is associated with poor survival in patients with breast cancer
Author: Wang, Huxia; Tang, Yanan; Wang, Meixia; Zhao, Jing; Ding, Caixia; Yang, Xiaomin; Han, Pihua; Liu, Peijun

Journal: BIOMARKERS IN MEDICINE. 2023; Vol. 16, Issue 16, pp. 1161-1170. DOI: 10.2217/bmm-2022-0468
4、Association between CYP19A1 rs6493497 and rs936306 polymorphisms and depression susceptibility in the Chinese population
Author: Peng, Qiuju; Yan, Yuan; Yan, Huacheng; Xie, Guibo; Shi, Lei; Wen, Yuguan; Chang, Qingxian

Journal: BIOMARKERS IN MEDICINE. 2023; Vol. 16, Issue 16, pp. 1171-1179. DOI: 10.2217/bmm-2022-0370
5、Novel nomogram for predicting coronary vulnerable plaque risk in patients with coronary artery disease
Author: Liu, Tao; Ji, Hanhua; Jian, Xinwen; Wang, Weiyi; Fan, Zeyuan

Journal: BIOMARKERS IN MEDICINE. 2023; Vol. 16, Issue 16, pp. 1139-1149. DOI: 10.2217/bmm-2022-0855
6、Novel biomarker panel for the diagnosis and prognosis assessment of sepsis based on machine learning
Author: Wu, Juehui; Liang, Jianbo; An, Shu; Zhang, Jingcong; Xue, Yimin; Zeng, Yanlin; Li, Laisheng; Luo, Jinmei

Journal: BIOMARKERS IN MEDICINE. 2023; Vol. 16, Issue 15, pp. 1129-1138. DOI: 10.2217/bmm-2022-0433
7、3 ' untranslated region variants in DEFA5 gene associated with susceptibility to IgA nephropathy in the Chinese Han population
Author: Peng, Hongwei; Fan, Pingyun; Hong, Yifen; He, Jing; Zeng, Xiangxiu; Xu, Fengguo; Zhao, Yunxia; Jin, Tianbo

Journal: BIOMARKERS IN MEDICINE. 2023; Vol. 16, Issue 16, pp. 1151-1159. DOI: 10.2217/bmm-2022-0518
8、Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis
Author: Zeng, Jiashun; Liu, Xiaoxia; Liu, Jun; Wu, Pengjia; Yang, Lei

Journal: BIOMARKERS IN MEDICINE. 2023; Vol. 16, Issue 17, pp. 1239-1249. DOI: 10.2217/bmm-2022-0216